NEO

$7.96-0.22 (-2.69%)

Market ClosedAs of Mar 20, 8:00 PM UTC

NeoGenomics, Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$7.96
Potential Upside
5%
Whystock Fair Value$8.36
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDiagnostics & Research

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, a...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.03B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-12.44%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.94

Recent News

Simply Wall St.
Mar 20, 2026

A Look At Neo Performance Materials (TSX:NEO) Valuation After Recent Share Price Volatility

Business profile and recent share performance Neo Performance Materials (TSX:NEO) has attracted attention after a recent share price move, with the stock down 14.1% over the past day and 22.5% over the past week, despite gains in the past 3 months and year. The company, headquartered in Toronto and founded in 1994, manufactures and sells rare earth, magnetic powders, magnets, and rare metal based functional materials across Asia, North America, Europe, and other international markets. Its...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 19, 2026

Is It Too Late To Reassess Neo Performance Materials (TSX:NEO) After Its 1-Year Surge?

If you are wondering whether Neo Performance Materials is still good value after a strong run, the key question is how its current share price compares with what the underlying business may be worth. The stock last closed at $23.84, with returns of 16.0% over 30 days, 41.1% year to date, and 166.8% over 1 year. This naturally raises questions about both upside potential and changing risk perceptions. Recent coverage has focused on Neo Performance Materials as a rare earth and advanced...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 19, 2026

Neo Performance Materials Q4 Earnings Call Highlights

Neo Performance Materials (TSE:NEO) highlighted higher profitability and strategic progress during its fourth-quarter 2025 earnings call, pointing to volume growth across key product lines, cost improvements from automation, and continued investment in its European permanent magnet and separation in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 19, 2026

3 Russell 2000 Stocks We Approach with Caution

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 18, 2026

NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market

NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, NeoGenomics officially launched RaDaR ST, a tumor-informed circulating tumor DNA/ctDNA assay designed to detect molecular residual disease/MRD across various solid tumor types. This launch targets a rapidly growing MRD market estimated at over $20 billion, […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.